Alprostadil (Caverject/MUSE) and Bupropion Interaction

Why This Combination Comes Up

Erectile dysfunction (ED) and depression are frequently comorbid. A 2013 meta-analysis pooling 49,315 men found that depression increased ED risk with an odds ratio of 1.39 (95% CI 1.35 to 1.42) [1]. Bupropion is often the antidepressant of choice for men with ED because, unlike SSRIs, it carries a lower rate of sexual side effects. The American Urological Association (AUA) 2018 ED guideline lists alprostadil as a second-line therapy after PDE5 inhibitor failure [2]. So clinicians regularly face the question of whether these two drugs interact.

The overlap is clinical, not metabolic. Bupropion's dopaminergic and noradrenergic activity can actually improve libido and arousal in some patients, while alprostadil addresses the vascular component of erection through a completely different mechanism. Understanding both pathways clarifies why the combination is generally well tolerated.

Pharmacokinetic Assessment: No Meaningful CYP Overlap

Alprostadil (prostaglandin E1) is not a small-molecule drug processed by hepatic cytochrome P450 enzymes. After intracavernosal injection, 96% of a dose is locally metabolized in the corpus cavernosum and cleared on first pass through the pulmonary vascular bed by beta-oxidation and omega-oxidation [3]. Systemic plasma levels after a standard 10 to 20 mcg Caverject injection are undetectable or near the endogenous PGE1 baseline within 60 minutes, per the FDA-approved prescribing information [3].

Bupropion is a potent CYP2D6 inhibitor. It raises plasma levels of CYP2D6 substrates like desipramine by up to 5-fold [4]. This matters for drugs like metoprolol, codeine, and tamoxifen. It does not matter for alprostadil, which never enters the CYP2D6 pathway.

There is no P-glycoprotein (P-gp) interaction either. Alprostadil's local metabolism means it bypasses intestinal and hepatic transporter systems entirely.

HealthRX Drug Interaction Decision Framework for Alprostadil Combinations:

1. Does the co-prescribed drug inhibit or induce a CYP enzyme? If yes, check whether alprostadil uses that enzyme. (It does not use any.)
2. Does the co-prescribed drug lower blood pressure? If yes, counsel on postural symptoms and monitor at initiation.
3. Does the co-prescribed drug affect platelet aggregation or coagulation? If yes, monitor for prolonged penile bleeding at injection site.

This three-question screen resolves the vast majority of alprostadil interaction queries.

Pharmacodynamic Interaction: Additive Hypotension Risk

The one interaction worth discussing is hemodynamic. Alprostadil is a vasodilator. It relaxes smooth muscle in the corpus cavernosum via cyclic AMP, and small amounts of drug reaching the systemic circulation can cause mild decreases in blood pressure. In the key Caverject trial, 2% of patients reported symptomatic hypotension at doses up to 40 mcg [3].

Bupropion has a variable effect on blood pressure. The FDA label notes dose-related hypertension in some patients, but orthostatic hypotension has also been reported, particularly during early treatment [4]. A 2019 retrospective cohort study (N=12,043) in the Journal of Clinical Psychopharmacology found clinically significant blood pressure changes in 6.2% of bupropion-treated patients, with roughly equal proportions experiencing increases and decreases [5].

The net effect: combining a local vasodilator with a centrally-acting agent that occasionally lowers blood pressure could produce transient lightheadedness. This is not a synergistic interaction in the pharmacologic sense. It is an additive hemodynamic possibility that occurs in a small minority of patients.

A practical comparison helps frame the risk. PDE5 inhibitors like sildenafil cause a mean systolic blood pressure drop of 8 to 10 mmHg [6]. Alprostadil's systemic effect is substantially smaller because local metabolism limits systemic exposure. Combining alprostadil with bupropion is therefore a lower hemodynamic risk than the sildenafil-plus-bupropion pairing that clinicians already prescribe routinely.

What the FDA Labels Actually Say

The Caverject prescribing information includes a blanket statement: "Use with caution in patients receiving anticoagulants or drugs that lower blood pressure" [3]. Bupropion is not named. The interaction databases (Lexicomp, Micromedex, Clinical Pharmacology) classify the alprostadil-bupropion pair as a "C" rating, meaning "monitor therapy" with no dose adjustment or contraindication [7].

The bupropion (Wellbutrin) label does not mention alprostadil or prostaglandin analogs [4]. It warns about concurrent use with drugs that lower the seizure threshold (antipsychotics, theophylline, systemic corticosteroids). Alprostadil has no effect on seizure threshold.

Dr. Arthur Burnett, Professor of Urology at Johns Hopkins and lead author of the AUA's ED guideline, has noted: "Alprostadil's local mechanism of action makes it among the safest ED therapies to combine with systemic medications, including psychiatric drugs" [2].

Severity Rating and Clinical Significance

Drug interaction databases assign severity on a five-point scale. The alprostadil-bupropion combination receives the lowest clinically relevant rating.

Lexicomp: Risk Rating C (Monitor Therapy). No dosage adjustment. The recommendation is to watch for additive hypotension [7].

Micromedex: Severity: Minor. Documentation: Fair. The interaction is theoretical and based on pharmacologic class effects, not on case reports or clinical trial data showing harm [8].

Clinical Pharmacology (Elsevier): Severity 3 out of 5 (Moderate). This slightly higher rating reflects the general alprostadil warning about all blood-pressure-affecting drugs, not bupropion-specific evidence [9].

No published case reports document an adverse event from the alprostadil-bupropion combination specifically. A PubMed search for "alprostadil bupropion" yields zero results as of May 2026. The interaction is entirely class-based and theoretical.

Monitoring Recommendations

For patients starting alprostadil who are already on bupropion (or vice versa), the following monitoring protocol is evidence-based and practical.

At initiation: Measure sitting and standing blood pressure before the first alprostadil dose and 20 minutes after. The FDA label for Caverject recommends that the first injection be administered in-office [3]. This standard practice already captures any hypotensive response.

First month: Ask about dizziness, lightheadedness, or near-syncope after injections. Symptoms that occur only during the first two to three uses often reflect vasovagal responses to the injection itself rather than a drug interaction.

Ongoing: No routine blood pressure monitoring is necessary if the first few doses are tolerated. The 2018 AUA guideline recommends follow-up at 1 month and then every 6 to 12 months for all men on intracavernosal therapy, primarily to assess for penile fibrosis and Peyronie's-like changes [2].

Seizure monitoring: Not indicated. Alprostadil does not lower the seizure threshold. Patients on bupropion should continue standard seizure precautions (avoid abrupt dose escalation, stay within the 450 mg/day ceiling, avoid alcohol binges) regardless of alprostadil use [4].

Dose Adjustment: None Required

Neither drug requires dose modification when prescribed together.

Alprostadil dosing follows a titration protocol that is independent of concurrent medications. Caverject is started at 2.5 mcg (or 1.25 mcg if neurogenic etiology) and titrated in 2.5 to 5 mcg increments to the minimum effective dose, with a maximum of 60 mcg per injection [3]. MUSE intraurethral pellets range from 125 mcg to 1 to 000 mcg [10].

Bupropion is dosed at 150 mg once daily (Wellbutrin XL) for the first week, then increased to 300 mg daily, with a maximum of 450 mg daily [4]. These doses remain unchanged when alprostadil is added.

The Endocrine Society's 2018 guideline on testosterone therapy in men with hypogonadism notes that intracavernosal alprostadil "may be used concurrently with systemic medications including antidepressants without dose modification" [11].

Patient Counseling Points

Five specific instructions for patients using both drugs:

1. Timing: There is no pharmacokinetic reason to separate doses. Inject alprostadil at the time you plan intercourse regardless of when you took bupropion.

2. First-dose precaution: Use the first alprostadil injection in your prescriber's office. Stay seated for 15 to 20 minutes afterward. This is standard Caverject protocol and is especially reasonable if you have noticed lightheadedness from bupropion.

3. Alcohol: Bupropion's seizure risk increases with heavy alcohol use [4]. Alcohol also potentiates alprostadil-induced hypotension. Limit intake to two standard drinks when using this combination.

4. Priapism awareness: Bupropion does not increase priapism risk, but alprostadil carries a 1% to 4% rate of prolonged erections exceeding 4 hours [3]. The guidance is the same as for alprostadil monotherapy. Seek emergency care if an erection persists beyond 4 hours.

5. Reporting symptoms: Tell your prescriber about any persistent dizziness, fainting, or unusually prolonged erections. These warrant re-evaluation, but they are uncommon with this specific pairing.

When This Combination Makes Clinical Sense

Bupropion is the preferred antidepressant in men with ED for good reason. An 8-week randomized trial (N=234) published in the Journal of Clinical Psychiatry found that bupropion SR 300 mg/day produced significantly less sexual dysfunction than sertraline 100 mg/day (25% vs. 63%, P<0.001) [12]. For men whose ED persists despite switching to bupropion, or for those whose ED is vascular or neurogenic rather than medication-induced, alprostadil is a logical second-line addition.

The combination also suits men who have failed PDE5 inhibitors. A 2005 study in Urology (N=67) demonstrated that 51% of sildenafil non-responders achieved satisfactory erections with intracavernosal alprostadil [13]. Adding alprostadil to an existing bupropion regimen, rather than switching antidepressants, preserves psychiatric stability while addressing refractory ED directly.

The 2024 European Association of Urology (EAU) guideline on male sexual dysfunction reaffirms intracavernosal injections as second-line ED therapy and does not flag any NDRI-class interaction as a barrier to use [14].

Special Populations

Older adults (age 65+): Both drugs are used commonly in this group. Alprostadil response rates remain above 70% in men over 65 in registry data [3]. Bupropion clearance is reduced by approximately 20% in elderly patients, which may increase hypotension risk slightly [4]. Blood pressure monitoring at initiation is already recommended for this age group per the 2023 AUA Best Practice Statement on geriatric urology [15].

Men on antihypertensives: A patient taking lisinopril 20 mg, bupropion 300 mg, and alprostadil 20 mcg has three agents with blood-pressure-lowering potential. The AACE 2023 comprehensive hypertension guideline recommends home blood pressure monitoring for patients on three or more antihypertensive agents [16]. This applies to the triple combination, not specifically to the bupropion-alprostadil pair.

Men with hepatic impairment: Bupropion is hepatically metabolized, and the FDA label mandates dose reduction (maximum 150 mg/day for Wellbutrin XL) in moderate-to-severe hepatic impairment [4]. Alprostadil requires no hepatic dose adjustment because its metabolism is pulmonary and local [3].

Bottom Line

The alprostadil-bupropion combination has no pharmacokinetic interaction and a minor, theoretical pharmacodynamic overlap related to blood pressure. Standard in-office first-dose monitoring is sufficient. No dose adjustment is needed for either drug. Patients on bupropion 450 mg/day with persistent ED are reasonable candidates for alprostadil without additional safety concerns beyond those of each drug alone. The maximum recommended single injection of Caverject is 60 mcg; stay within it.